摘要
目的研究慢性阻塞性肺疾病伴急性加重期（AECOPD）的两种抗菌药物治疗方法的药物经济学效果。方法采用回顾性研究方法，将102例AECOPD患者按照不同治疗方法分为美洛西林舒巴坦钠治疗组（A组）和头孢米诺钠治疗组（B组），住院天数为7—14d，分别观察两组治疗后的疗效和不良反应发生率并以其评估治疗的效果，然后运用药物经济学中的成本-效果分析方法、敏感度分析方法及用药频度（DDDs）进行分析。结果A组和B组临床总有效率分别为93．55％、95．00％（P〉0．05），不良反应发生率分别为3．23％、2．50％；平均住院时间分别为（9．19±2．17）d和（8．90±1．98）d，总成本分别为（7695．18±2993．02）元、（9648．49±2631．41）元，统计学分析两组有显著性差异（P〈0．05）；A组C／E和AC／AE均低于B组且敏感度分析结果与成本．效果分析的结果保持一致。另外，DDDsA〈DDDsB，两组DDDs值无显著性差异（P〉0．05）。结论治疗AECOPD，美洛西林舒巴坦钠较头孢米诺钠经济、有效、合理。
OBJECTIVE To Studies of chronic obstructive pulmonary disease with acute exacerbation （AECO- PD） of two antibaccterial drug treatments of pharmacoeconomic effect. METHODS by a retrospective exploration, 102 medical records were divided into Mezlocillin sodium/Sulbactam sodium （A）group and Cefninox sodium （B） group as different treatment methods, the length of hospital stay was 7 - 14 days, the curative effect and adverse reaction of 2 groups after treatment were observed and evaluated the effect of treatment with those, then cost-effectiveness analysis （CEA）, sensitivity analysis and frequency of medication DDDs were performed. RESULTS The clinical total effective rates of A group and B group were 93.55% and95.00% respectively （ P 〉 0.05 ） , the incidence of adverse reaction were 3.23% ,2.50%, Mean length of hospital stay were （9. 19 ± 2. 17 ）days and （8.90 ± 1.98 ）days, and the total costs were （7695.18 ± 2993.02） Yuan and （9648.49 ± 2631.41 ）Yuan, statistical analysis of the two groups had significant difference （ P 〈 0. 05 ） ; The cost-effectiveness ratio of Mezlocillin sodium/Sulbactam sodium （A） group was lower than that of Cefninox （B）group, the sensitivity analysis results were consistent with results of parameter change. In addition, DDDsA 〈 DDDsB, there was no significant difference between A group and B group a- bout DDDs. CONCLUSION The treatment of AECOPD, Mezloeillin sodium/Sulbactam sodium is more economical,reasonable,effective than cefninox sodium.
出处
《海峡药学》
2014年第7期179-182,共4页
Strait Pharmaceutical Journal
